Daxor Corp (DXR): Michael Richard Feldschuh , CEO of Daxor Corp purchased 200 shares on Apr 11, 2016. The Insider buying transaction was disclosed on Apr 12, 2016 to the Securities and Exchange Commission. The shares were purchased at $8.06 per share for a total value of $1,612.00.
Currently the company Insiders own 81.15% of Daxor Corporation shares according to the proxy statements.Institutional Investors own 3.87% of Daxor Corporation shares.
Shares of Daxor Corporation (DXR) ended Monday, Apr 11, 2016 session in red amid volatile trading. The shares closed down -0.0146 points or -0.18% at $8.05 with 900 shares getting traded. Post opening the session at $8.06, the shares hit an intraday low of $8.05 and an intraday high of $8.06 and the price vacillated in this range throughout the day. The company has a market cap of $31 M and the number of outstanding shares has been calculated to be 38,52,488 shares. The 52-week high of Daxor Corporation is $9.1799 and the 52-week low is $5.99.
Daxor Corporation is a medical instrumentation and biotechnology company. The Company designed and developed the BVA-100 Blood Volume Analyzer. BVA-100 Blood Volume Analyzer provides direct measurement of a patient’s blood volume. The BVA-100 is a semi-automated Blood Volume Analyzer. It is used in conjunction with a single use diagnostic kit. The BVA-100 is used to diagnose and treat patients with heart failure kidney failure hypertension and syncope and to aid in fluid and blood transfusion management. The BVA-100 has also been used to aid in the diagnosis and treatment of disorders of red blood cell volume including polycythemia and anemia and to aid in pre-surgical evaluation of red blood cell volume. The Companys IDANT division (IDANT Laboratories subsidiary) provides semen banking services which include anonymous donor semen and semen storage autologous blood storage andrology services which include semen analysis and sperm washing and general lab testing.